Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer

• Ernest Nadal ^[7] ; Martín Oré-Arce ^[8] ; Jordi Remon ^[9] ; Reyes Bernabé-Caro ^[1] ; Marta Covela-Rúa ^[2] ; Javier de Castro-Carpeño ^[3] ; Bartomeu Massutí-Sureda ^[4] ; Mónica Guillot-Morales ^[5] ; Margarita Majem ^[10] ; Inmaculada Maestu-Maiques ^[6] ; Idoia Morilla-Ruíz ^[11] ; Regina Gironés ^[12]
  1. [1] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  2. [2] Hospital Universitario Lucus Augusti

     Hospital Universitario Lucus Augusti

     Lugo, España

     
  3. [3] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  4. [4] Hospital General Universitario de Alicante

     Hospital General Universitario de Alicante

     Alicante, España

     
  5. [5] Hospital Universitario Son Espases

     Hospital Universitario Son Espases

     Palma de Mallorca, España

     
  6. [6] Hospital Universitario Doctor Peset

     Hospital Universitario Doctor Peset

     Valencia, España

     
  7. [7] Departamento de Oncología Médica, Institut Català d’Oncologia (ICO), Institut d’Investigacions Biomèdiques de Bellvitge (IDIBELL), Hospital Universitario Duran i Reynals, Barcelona, España
  8. [8] Departamento de Oncología Médica, Hospital Marina Baixa de Villajoyosa, Alicante, España
  9. [9] Departamento de Oncología Médica, Hospital HM Nou Delfos, Barcelona, España
  10. [10] Departamento de Oncología Médica, Hospital Santa Creu i Sant Pau, Barcelona, España
  11. [11] Departamento de Oncología Médica, Hospital Universitario de Navarra-NavarraBioMed, IdisNa, Pamplona, España
  12. [12] Departamento de Oncología Médica, Hospital Universitario Politécnico la Fe, Avinguda de Fernando Abril Martorell, 106, 46026, Valencia, Valencia, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 11 (November), 2023, págs. 3139-3151
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Lung cancer (LC) is associated with ageing, with the average age of affected individuals being approximately 70 years. However, despite a higher incidence and prevalence among older people, the older adult population is underrepresented in clinical trials. For LC with Epidermal Growth Factor Receptor (EGFR) mutations, there is no clear association of this mutation with age. Geriatric assessments (GAs) and a multidisciplinary approach are essential for defining the optimal treatment. In this consensus, a group of experts selected from the Oncogeriatrics Section of the Spanish Society of Medical Oncology (Sección de Oncogeriatría de la Sociedad Española de Oncología Médica—SEOM), the Spanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón—GECP) and the Association for Research on Lung Cancer in Women (Asociación para la Investigación del Cáncer de Pulmón en Mujeres—ICAPEM) evaluate the scientific evidence currently available and propose a series of recommendations to optimize the management of older adult patients with advanced LC with EGFR mutations.